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Abstract
Background: In a research study, to give a comprehensive evaluation of the impact of interventions, the outcome
measures should reflect the lived experience of the condition. In dementia studies, this necessitates the use of
outcome measures which capture the range of disease effects, not limited to cognitive functioning. In particular,
assessing the functional impact of cognitive impairment is recommended by regulatory authorities, but there is
no consensus on the optimal approach for outcome assessment in dementia research. Our aim was to describe
the outcome measures used in dementia and mild cognitive impairment (MCI) intervention studies, with
particular interest in those evaluating patient-centred outcomes of functional performance and quality of life.
Methods: We performed a focused review of the literature with multiple embedded checks of internal and
external validity. We used the Cochrane Dementia and Cognitive Improvement Group’s register of dementia
studies, ALOIS. ALOIS was searched to obtain records of all registered dementia and MCI intervention studies
over a 10-year period (2004–2014). We included both published and unpublished materials. Outcomes were
categorised as cognitive, functional, quality of life, mood, behaviour, global/disease severity and
institutionalisation.
Results: From an initial return of 3271 records, we included a total of 805 records, including 676 dementia trial
records and 129 MCI trial records. Of these, 78 % (630) originated from peer-reviewed publications and 60 %
(487) reported results of pharmacological interventions. Cognitive outcomes were reported in 70 % (563), in
contrast with 29 % (237) reporting measures of functional performance and only 13 % (102) reporting quality of
life measures. We identified significant heterogeneity in the tools used to capture these outcomes, with frequent
use of non-standardised tests.
Conclusions: This focus on cognitive performance questions the extent to which intervention studies for dementia
are evaluating outcome measures which are relevant to individual patients and their carers. The heterogeneity in
measures, use of bespoke tools and poor descriptions of test strategy all support the need for a more standardised
approach to the conduct and reporting of outcomes assessments.
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Background
Contemporary evidence-based medicine is built upon a
foundation of robust clinical trials. The field of dementia
and cognitive impairment has fewer evidence-based in-
terventions than many other common diseases. In this
context, it is essential that dementia trials be based on
sound design, conduct and reporting. Assessing an inter-
vention requires some measure of treatment effect. The
importance of selecting relevant outcome measures in
all clinical trials is recognised [1]. Poor choice of out-
come measure can weaken or invalidate the results of an
otherwise well-conducted trial.
A plausible outcome for a dementia trial is diagnosis
of incident dementia or assessment of dementia severity.
Dementia diagnosis is evolving, [2, 3]; however, most
classifications require evidence of cognitive deficits
which cause impairment in daily activities and independ-
ence [4]. Outcomes other than clinical assessments, such
as neuroimaging and tissue biomarkers, have been used
to quantify dementia severity; however, the validity of
these surrogate measures has been questioned [5], and
in certain fields surrogate outcomes have given results
that were not confirmed in subsequent trials with
clinical outcomes [6].
Many tools are available for quantifying cognition.
These tests can range from short screening tests through
to detailed multidomain neuropsychological batteries.
The authors of a review of neuropsychological tests in
dementia described 59 differing assessments that had
been used in studies [7]. Even in a relatively niche area
such as post-stroke cognitive and mood disorder, there
is substantial heterogeneity in assessment, with the au-
thors of a recent review describing almost as many
measurement tools as there were trials [8].
A popular dementia trial outcome paradigm describes
conversion from a state of mild cognitive impairment
(MCI) to dementia. The defining criterion for conversion
is decline in functional ability, so assessment of function
is crucial [9]. In fact, robust assessment of daily function
is important in all dementia studies. Activity limitation
and dependency is feared by patients and carers and has
substantial economic impact [10]. There is evidence that
dependency, rather than cognitive decline, is the more
significant predictor of health-related quality of life [8].
Interventions designed to promote independence were
identified as the first of ten research priorities by
patients, the public and researchers [9]. Therefore, inter-
ventions whose efficacy is tested on change in cognitive
function may not capture outcomes of greatest relevance
for people with dementia and their carers. Again, many
tools are available for assessment of function. Describing
function can range from assessment of specific task
impairments through daily activity to wider societal
participation [11].
In studies of established dementia, assessment of
treatment response may look at cognitive and physical
function or may describe other manifestations of disease,
such as behavioural or mood symptoms. Such measures
may directly assess the patient or may take collateral
information from a suitable informant, such as family
members or carers. Progression of dementia involves a
complex interplay of cognitive, physical, behavioural and
carer factors. In an attempt to quantifying this concept,
global assessment scales have been described.
Traditional assessments tend to have a biomedical focus
and may not adequately capture the lived experience of
dementia for the individual patient. There is growing
international recognition of the need for outcome
measures in dementia studies to assess domains beyond
simple impairment measures [12]. The U.S. Food and
Drug Administration (FDA) advocate that clinical trials in
dementia should use a co-primary outcome measure, in-
corporating cognitive and functional or global assessment
measures in drug trials [13]. Patient-reported outcome
measures are increasingly recommended, and tools for
describing generic and health-related quality of life in
dementia are available [14].
Thus, a variety of approaches to performing outcome
assessment in dementia trials are available, including
cognitive, functional, behavioural and quality of life mea-
sures. We aimed to describe the outcome measures used
in intervention studies for dementia and MCI. We were
particularly interested in the use of functional and qual-
ity of life measures because these seem to be the factors
of greatest importance to those affected by dementia.
Methods
We conducted a focused search of contemporary de-
mentia trials, following a methodology that has been
used previously to describe outcomes in other disease
areas [8, 15]. Although not a systematic review, where
applicable, we followed best practice in conduct and
reporting as described in Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
guidance [16]. A study protocol was pre-specified and
registered with the Research Registry resource [17]
(reviewregistry78).
Data source
Our primary data source was the Cochrane Dementia
and Cognitive Improvement Group’s (CDCIG’s) register
of all dementia trials, ALOIS [18]. ALOIS is a freely
accessible electronic database whose aim is to collate
information on all trials with a dementia or cognition
focus. ALOIS is updated on a continuous basis with tri-
als identified from monthly searches across multiple da-
tabases (including MEDLINE, Embase, PsycInfo, Cinahl
and Lilacs, in addition to international trial registries,
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pharmaceutical registries and grey literature sources)
[19]. A core team of experienced CDCIG information
scientists, supplemented by volunteer support, screen
monthly search results and identify relevant trials. Trial
characteristics are manually extracted from full-text
publications to an electronic template following a
structured framework devised by the CDCIG to create
consistent annotations across the data set. Trials are
assigned a primary ‘study aim’ label, such as “Treatment,
Dementia”, or “Treatment, MCI”. The meta-data
extracted from each trial within ALOIS is categorised
using the PICOTS system, where ‘P’ is characteristics
about the trial population; ‘I’ is characteristics about the
intervention(s); ‘C’ is characteristics about the compara-
tors; ‘O’ is characteristics about the outcomes measured
and the instruments used; ‘T’ is characteristics about the
timing and duration of the trial; and ‘S’ is further details
about the study design used, such as whether it was
double-blind or single-blind. Data are presented as a
mix of categorised responses and free text fields, and
outcome data are free text with description of outcomes
taken verbatim from source.
Search strategy
A single researcher experienced in systematic review
(JKH) performed a two-stage search, first identifying
relevant studies for inclusion using the filters within
ALOIS and collating study IDs; in the second stage, re-
cords were accessed and eligibility was assessed, and all
ineligible studies were reviewed by a second reviewer
(TJQ) to confirm. Any disagreement was resolved by
discussion. We searched ALOIS to identify all dementia
and MCI trials published, presented at conferences or
registered in a clinical trials database during the period
between January 2004 and December 2014 inclusive. We
used search filters to limit results to intervention studies,
specifically excluding diagnostic accuracy studies. We
further filtered results on the basis of primary classifica-
tion within ALOIS, restricting our search to those stud-
ies labelled ‘treatment, dementia’ or ‘treatment, MCI’
and excluding those classified as ‘cognitive enhancement,
primary prevention, caregiver focused and other’.
We further refined the list of titles produced by
ALOIS, limiting it to studies of human subjects and to
those published within our date range. Where a trial
data set had more than one ALOIS entry, we favoured
the primary publication and excluded duplicates. We
classified included trials as pertaining to dementia
(where the trial population had a diagnosis of a dementia
syndrome, including any pathological sub-classification)
and MCI (where the trial population had a diagnosis of
MCI or any synonyms describing a state of cognitive
impairment that does not fulfil diagnostic criteria for
dementia). We excluded studies which were ongoing, in
planned/protocol stage, stopped early or whose status
was classified as ‘unclear’. Unpublished data were
included if sufficient information existed to merit an
ALOIS entry graded as ‘study complete’.
Data collection
We extracted data from ALOIS, supplemented by access
to source journal where required, to a pre-specified
electronic pro forma. We described data source, year of
publication, country, nature of intervention, population
studied and outcomes assessed. We purposively did not
assess methodology or reporting quality of studies. Be-
cause our focus was outcomes as described in published
materials, when data were unclear, we did not contact
authors of articles or national clinical trial (NCT)
registrations for clarification. Where outcome data were
not listed on ALOIS or the record appeared incomplete,
the original article or NCT link was accessed, if
available, to obtain outcome measures.
We categorised data source by journal type. We pre-
specified a journal classification based on the journal’s
primary focus and grouped them into specialist subject
areas using the following labels: complementary & alter-
native medicine, general medicine, geriatric medicine &
gerontology, neurology & neuroscience, nursing, nutri-
tion, old age psychiatry & dementia, pharmacology,
psychiatry, psychology and rehabilitation, and ‘other’
where none of these labels were applicable. Categorisa-
tion was assessed independently by two authors (JKH
and ELR) with involvement of a third (TJQ) in the event
of disagreement.
We categorised outcomes using the following labels:
cognitive function, activities of daily living (ADL) or
functional performance, quality of life, mood, behaviour,
global/disease severity measures and institutionalisation
(binary). For each of these categories, we included recog-
nised assessments tools or scales, such as the Mini
Mental State Examination (MMSE) [20] for cognition or
the Barthel Index [21] for ADLs or where authors re-
ported using measures of cognition, function, mood and
so forth. We further classified the cognitive tests on the
basis of whether the assessment, as described, was a
recognised, validated cognitive test; not a recognised
test, but extrapolation of the cognitive construct being
tested was possible; and a category of ‘unclear’ where
the nature of testing was uncertain on the basis of infor-
mation given. Outcomes were classified independently
by two authors (JKH and TJQ) with further review by an
expert neuropsychologist (ND).
Analysis
We described the search process using a PRISMA style
flow diagram. We assessed aggregate data for included
studies, using simple descriptive statistics. We described
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number and proportion of total for each category of out-
come and tabulated the five most common outcomes for
each category. We assessed for temporal trends in out-
come assessment, number of trials in each outcome cat-
egory as a proportion of the total number of trials
included from that year, and assessed with the chi-
square test for trend. With a similar approach, we
assessed outcome used by category of data source. As
assessment of function is particularly important for trials
in an MCI population, we compared proportions with/
without a measure in function in MCI and dementia tri-
als. As a post hoc analysis, we described cognitive and
functional outcomes, comparing published and unpub-
lished materials.
Results
Search
We ran our primary search on 15 May 2015. A total of
3271 records were returned in ALOIS, of which 976
were considered eligible after the first stage. When re-
cords were accessed and reviewed in the second stage,
171 were identified by both reviewers as ineligible and
were excluded. After filtering and classification, we
included a total of 805 records in the review, including
676 dementia trial records and 129 MCI trial records
(Fig. 1).
Study characteristics
The majority of included records were from peer-
reviewed publications; however, a significant proportion
came from unpublished records and conference ab-
stracts. Pharmacological interventions predominated,
making 60 % of those included. Europe and North
America were the regions where most included studies
were conducted. Individuals with Alzheimer’s disease
were the commonest included study population. Most
publications were in old age psychiatry & dementia,
neurology & neuroscience, and geriatric medicine &
gerontology journals (Table 1).
Analyses
The frequency of use of each outcome measure and the
five commonest measures used for each domain are re-
ported in Tables 2 and 3. Non-reporting of the tool used
was common: cognitive (3 %), ADL (34 %), quality of life
(23 %), mood (6 %), behaviour (10 %), disease severity
Fig. 1 Record selection procedure. MCI Mild cognitive impairment
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and global performance (4 %). Only 49 % of the cogni-
tive measures used were considered recognised cognitive
tests. Extrapolation of methods was possible in 36 % of
cases, and the remaining 15 % were considered unclear.
When published and unpublished studies were con-
sidered separately, there was evidence of an association
between publication status and the reporting of cogni-
tive outcomes. Cognitive outcomes were reported in
72 % of published studies and 64 % of unpublished
studies (p = 0.04). There was no evidence of an associ-
ation between publication status and the reporting of
ADL outcomes, which were reported by 30 % of pub-
lished studies and 27 % of unpublished studies (p 0.44).
Only 19 (2 %) of studies evaluated institutionalisation
as an outcome measure. A complete list of all outcome
measures reported is included in Additional file 1. Only
211 (26 %) records included measures of both cognitive
performance and functional status; only 169 (21 %) re-
cords included measures of cognition and function and
any other outcome measure (Fig. 2).
The results of comparative analyses of categorical data
are presented in Table 4. There was evidence of greater
reporting of mood and quality of life measures in more
contemporary trials. There was no evidence of associ-
ation between time and reporting of the other outcome
categories. There was evidence of association between
the reporting of mood and behavioural outcomes and
publication status, not seen when evaluating the other
outcome categories.
Functional measures were more likely to be used in
dementia records (217 [32 %] of 676) than in MCI re-
cords (20 [16 %] of 129) (proportional difference 16 %,
95 % CI 7.4–24.6 %).
Discussion
In our evaluation of outcome measures from a decade of
contemporary dementia trials, we found substantial het-
erogeneity in assessment, poor descriptions of assessment
Table 1 Characteristics of included records
n (%)
Source
Peer-reviewed publications 630 (78)
Unpublished 128 (16)
Conference abstracts 47 (6)
Intervention
Pharmacological 487 (60)
Non-pharmacological 311 (39)
Both 7 (1)
Registration/publication
2004 40 (5)
2005 54 (7)
2006 68 (8)
2007 79 (10)
2008 99 (12)
2009 125 (16)
2010 68 (8)
2011 96 (12)
2012 59 (7)
2013 80 (10)
2014 33 (4)
2015a 4 (0.5)
Region
Asia 133 (17)
Australasia 27 (3)
Europe 249 (31)
Internationalb 46 (6)
Middle East 11 (1)
North America 231 (29)
Russia 13 (2)
South America 16 (2)
Unclear 79 (10)
Dementia subtype
Alzheimer’s disease 398 (49)
Dementia (unspecified) 158 (20)
Dementia and mild cognitive impairment 30 (4)
Frontotemporal dementia 11 (1)
Mild cognitive impairment 123 (15)
Mixedc 39 (5)
Parkinson’s disease dementia/dementia with Lewy bodies 22 (3)
Vascular dementia 24 (3)
Journal of publication (n = 630)
Old age psychiatry & dementia 195 (31)
Geriatric medicine & gerontology 110 (17)
Neurology & neuroscience 95 (15)
Table 1 Characteristics of included records (Continued)
General medicine 47 (7)
Pharmacology 44 (7)
Complementary & alternative medicine 27 (4)
Psychiatry 22 (3)
Rehabilitation 20 (3)
Nursing 18 (3)
Nutrition 9 (1)
Psychology 8 (1)
Other 35 (6)
All percentages are rounded to nearest whole number
aDenotes study published in 2015 but registered in period of interest
bInternational defined as study sites in more than two regions
cStudy included those with more than one specific dementia subtype
Harrison et al. Alzheimer's Research & Therapy  (2016) 8:48 Page 5 of 10
tools and a reliance on cognitive measures. There was
evidence of greater reporting of mood and quality of life
measures in more contemporary trials, but no other
trends of improved reporting. Less than one-third
included a measure of functional performance, which is
needed to establish if the intervention to improve
cognitive performance has any practical impact to the
individual, and this result was not driven by the inclusion
of unpublished material.
Functional measures appeared to be underused in
MCI studies, with only 16 % containing any measure of
functional/ADL performance. Cognitive function can be
considered as an ‘impairment’ measure, summarising
where deficiencies in performance are found. In
contrast, quality of life and ADL measures focus on what
individuals feel or are able to do, and these may be of
greater relevance to patients. In particular, when deci-
sions are made about funding of treatments, it is more
useful to evaluate the impact of treatment on an individ-
ual, rather than the individual’s performance in cognitive
testing. It is often unclear how performance on stan-
dardized cognitive tests translates into practical or func-
tional outcomes. In the parallel field of stroke, functional
assessment is mandatory in stroke trials approved by the
Table 2 Cognitive and functional outcome measures across included records
Cognitive ADL/functional
Number of records reporteda 563 (70 %) 237 (29 %)
Total number of assessmentsb 1278 265
Number of unique assessmentsc 321 40
Assessment tool n Assessment tool n
1. Mini Mental State Examination 314 1. No tool 80
2. Alzheimer’s Disease Assessment Scale –
Cognitive Subscale
181 2. Alzheimer Disease Cooperative Study
Activities of Daily Living scaled
67
3. Trail Making Tests 45 3. Barthel Index 24
4. No tool 40 3. Disability Assessment for Dementia 24
5. Severe impairment battery 27 5. Functional Assessment Staging 7
aNumber of records in ALOIS where a measure was reported at least one
bTotal number of times an outcome measure is used in all included records
cTotal number of unique assessment measures used at least once
dDoes not include variants of Alzheimer Disease Cooperative Study Activities of Daily Living tool
Table 3 Use of other outcome measures across included records
Quality of life Mood Behaviour Global
Number of records
reporteda
102 (13 %) 174 (22 %) 303 (38 %) 247 (31 %)
Total number of
assessmentsb
118 207 365 279
Number of unique
assessmentsc
21 41 32 25
Assessment tool n Assessment tool n Assessment tool n Assessment tool n
1. Quality of Life in
Alzheimer’s Disease
36 1. Geriatric Depression
Scale
47 1. Neuropsychiatric
Inventory
183 1. Clinician’s Interview-Based
Impression of Change plus
caregiver interview
41
2. No tool 27 2. Cornell Scale for Depression
in Dementia
41 2. Cohen-Mansfield
Agitation Inventory
53 2. Clinical Dementia Rating –
Sum of Boxes
30
3. EQ-5D 15 3. Brief Psychiatric Rating Scale 13 3. No tool 37 3. Clinical Global Impression 29
4. DEMQOL/DEMQOL
proxy
10 3. Hamilton Rating Scale for
Depression
13 4. Neuropsychiatric
Inventory – Nursing
Home
16 4. Clinical Dementia Rating 28
5. QUALID and
QUALIDEM
4 5. No tool 12 4. BEHAVE-AD 16 5. Clinical Global Impression
of Change
27
Abbreviations: EQ-5D EuroQol questionnaire, DEMQOL Dementia Quality of Life measure, QUALID Quality of life in late-stage dementia, QUALIDEM a dementia spe-
cific quality of life questionnaire rated by professionals, BEHAVE-AD Behavioral Pathology in Alzheimer’s Disease
aNumber of records in ALOIS where a measure was reported at least one
bTotal number of times an outcome measure is used in all included records
cTotal number of unique assessment measures used at least once
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FDA, recognising the role of functional recovery after
stroke. One difficulty with ADL measures is the presence
of ceiling effects [22], and these may be encountered
when applied to a population with MCI. However, if the
outcome of interest is the conversion from MCI to de-
mentia, assessment of ADL performance is fundamental.
MCI trials arguably should all use measures of func-
tional performance to assess the impact of the cognitive
impairment on the individual and how the treatment
under study affects it.
Only 2 % evaluated the effect of their intervention on
institutionalisation. Although institutionalisation in indi-
viduals with dementia is likely to be multifactorial [23],
it is nonetheless a relevant measure for this population
and an outcome feared by those with dementia. There
may be scope to use institutionalisation as an outcome,
particularly in large, multicentre trials. Determining this
outcome may require lengthy longitudinal follow-up if
studies target those with early-stage disease.
Of particular concern is that, across all outcome cat-
egories, we found a heterogeneity of measures being
used. There were also widespread uses of bespoke or un-
specified assessments. This not only is problematic for
comparisons between studies but also seems unjustified,
given the extent of validated tools in each outcome
domain. This topic has attracted international attention,
with many collaborations attempting to standardise
outcome reporting. The International Consortium for
Health Outcomes Measurement (ICHOM) initiative has
sought to develop outcome sets for specific conditions
to standardise the measurement and reporting of out-
comes and allow benchmarking in clinical practice, in-
cluding for dementia [24]. The Core Outcome Measures
in Effectiveness Trials initiative has on ongoing project
to develop a core outcome set for dementia, although its
interest is specifically in the community [25]. The
National Institutes of Health Toolbox contains a cog-
nition battery with tests for six domains of cognitive
functioning [26]. Taking ICHOM as an example, they
recommend use of the following for dementia: the
Neuropsychiatric Inventory (NPI), the Montreal Cogni-
tive Assessment, the Bristol Activity of Daily Living
Scale, Quality of Life in Alzheimer’s Disease (QOL-AD),
Quality of Well-Being Scale – Self-Administered, Euro-
Qol (EQ-5D) and Clinical Dementia Rating [27]. While
the QOL-AD and the NPI were the commonest mea-
sures of quality of life and behaviour in the trials in-
cluded in our study, use of the other measures was
limited. These recommendations are not universally ac-
cepted. All of these calls for standardisation have vocal
supporters and opponents, but, to date, few have gained
clinical traction, and use of these more standardised ap-
proaches has yet to change research or clinical practice.
One proposed advantage in the standardisation of out-
come assessment is to help facilitate pooling of results
and meta-analyses to identify the overall value, or lack
thereof, of an intervention. Use of different measures
makes this more difficult and can lead to the results
obtained from studies using different outcomes being
precluded and their data wasted [28]. A potential
Fig. 2 Diagrammatic representation of overlaps in the reporting of
cognitive, functional and ‘any other’ outcome measure. QoL Quality
of life
Table 4 Chi-square analyses of reporting by year and publication status
Yeara (n = 801) Published (yes/no) (n = 805)
χ2 test for trend p value χ2 test p value
Cognition 2.912 0.088 3.750 0.053
Function 1.227 0.268 0.436 0.509
Quality of life 22.693 0.000 1.766 0.184
Mood 12.158 0.000 8.238 0.004
Behaviour 0.226 0.634 11.076 0.001
Global 0.793 0.373 0.757 0.384
Institutionalisation 0.454 0.500 0.240 0.625
aExcluded 2015 as not part of study period
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disadvantage may be that the proposed standard
measures are not sufficiently sensitive to pick up small
changes in specific cognitive domains, particularly rele-
vant in those with very mild symptoms who are a com-
mon target in clinical trials, introducing inefficiencies
into research design. Alternatively, any standardised ap-
proach represents an opportunity cost to the researchers
and patients involved if other measures may be more
appropriate.
Although we have highlighted the most commonly
used outcome measures, these are not necessarily the
most appropriate for dementia studies. There will never
be an ideal outcome measure that meets all the require-
ments of various dementia studies. However, many of
the traditionally popular outcome assessments (e.g.,
MMSE, Barthel Index) were never designed as study
outcome measures, and their psychometric properties
have been poorly or simply not described. Where many
test options are available, choice of the test with best ac-
curacy, reliability and so forth seems intuitive. We note
that more contemporary cognitive assessments, includ-
ing the Oxford Cognitive Screen [29] and Addenbrooke’s
Cognitive Assessment III [30], have robust supporting
psychometric data. In validation work, these newer mea-
sures have been shown to correlate well with functional
outcomes. This is encouraging but does not remove the
need for separate measures of functional ability.
Cognitive measures were the most varied of those
studies, with 321 separate measures used. Just under half
of these were considered as accepted cognitive tests.
One particular issue was the failure to report the test
battery from which measures were derived, instead list-
ing only the test itself, a common reason for a measure
to be classed as ‘extrapolation possible’. Best practice in
reporting would provide an explicit description of the
nature of the test and method used, to allow reproduci-
bility of approach and to reference a source which de-
scribes the validity of the tool for the population of
interest,
The issues identified are not unique to the field of
dementia research. The need for improved reporting of
outcomes important to patients and the heterogeneity of
used measures has been noted in stroke research [8, 15],
and there is a growing recognition of the value of
patient-reported outcome measures when evaluating
clinical practice [31].
Strengths and weaknesses
We selected the most recent complete 10-year period to
evaluate, providing a contemporary sample of practice.
Our study period allows for a description of temporal
trends across a decade. Use of ALOIS as a data source
brings a breadth of included materials (original research
publications, protocols, trial registrations, grey literature)
which would not be captured if we restricted our search
to electronic databases such as PubMed or Embase.
There is attrition between clinical trial registration and
subsequent publication [32]. There is also known to be a
significant delay in the publication of clinical trials from
abstract stage and that many abstracts remain unpub-
lished [33]. Although data derived from an unpublished
record may be less comprehensive than those in a peer-
reviewed publication, they indicate the a priori inten-
tions of the researchers in the design of their study and
the outcome measures deemed important. ALOIS also
facilitates the inclusion of foreign language publications
because it draws on the resources of the Cochrane De-
mentia Group and text can be translated, again broaden-
ing representation of the research field. Finally, our
methods of checking information within the team and
accessing specialist expertise help to provide external
validity to our findings.
However, we acknowledge that the primary purpose of
ALOIS is not about the ascertainment of outcome mea-
sures, but rather to register clinical studies in the field of
dementia. As such, it is possible that not all outcomes
will have been included, and there may be errors in their
recording. We supplemented the use of ALOIS where
the outcomes list appeared to have been truncated, lo-
cating clinical trial registration data or full-text articles
where available. We limited our analysis to the data as
presented and did not contact authors for clarification.
We downgraded materials where ambiguity was found,
and this may overestimate the problems of reporting if
validated measures were used but not recorded in
ALOIS. There is also potential for the misclassification
of studies within ALOIS because records can be given
only one category. We were interested in common forms
of dementia and thus excluded records specific to highly
specialised presentations (e.g., Huntington disease,
Down syndrome). We also found records which were
not specific to a population with MCI or dementia (e.g.,
older adults, care home residents), which we excluded
from our analyses. Our focus was on describing out-
comes, and we did not assess the quality of design, con-
duct or reporting of the included studies. It would be of
interest to assess whether overall study quality was asso-
ciated with use of well-described, multimodal outcome
assessment.
Suggestions for future trials
The choice of outcome measures for an intervention
study will vary, depending on the population, study de-
sign and methods. Given the range of challenges experi-
enced by individuals with dementia and the complexity
of the domains affected by the causative conditions
within the umbrella of dementia, no single group of
measures will be appropriate for every study. We
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advocate greater use of outcome measures which
capture the effect of the intervention on the lived experi-
ence of the individual with dementia or MCI. Trialists
should ensure outcome measures, including test batter-
ies, are fully described and make greater use of validated,
standardised measures. We encourage researchers to de-
scribe not only which tests were used, with supporting
references, but also how these tests were employed in
practice. It is also vital that, for any outcome instrument,
we understand the feasibility of use, reliability and other
test properties so that results can be more readily ap-
plied to clinical practice. Reporting guidance, such as the
Consolidated Standards of Reporting Trials (CONSORT)
statement [34], has a key role in ensuring that re-
searchers are explicit in describing reproducible methods
and using validated assessment.
Conclusions
In this review, we sought to quantify the breadth of
reporting of outcome measures in dementia research.
Having identified the dominance of cognitive measures
and lack of use of measure of ADL performance, these
issues require urgent attention. We also identified prob-
lems of unclear reporting and heterogeneity of measures,
which increase the potential for research waste. These
require a more standardised approach to be adopted
within the field which has greater potential for patient
benefit as results can be harmonised and compared.
Additional file
Additional file 1: Full list of outcome measures reported. Tables
including all outcome measures reported in each of the categories:
cognitive, functional/ADL, quality of life, mood, behaviour and global.
(DOCX 37 kb)
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